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Purpose: To investigate tumor thickness and location, the interval of time between treatment 
for choroidal melanoma (proton beam irradiation or enucleation) and diagnosis of metastatic 
disease, and rates and sites of metastasis.
Design: Retrospective, interventional, noncomparative case series.
Methods: Follow-up of 152 patients with primary choroidal melanoma, between 1992 and 
2006 (14 years). One hundred and twenty-one patients were treated with proton beam irradiation 
and 31 patients were treated with enucleation. Baseline and annual or semiannual ophthalmic 
examination, B-scan ultrasonography, systemic and laboratory evaluations (liver enzymes, chest 
X-ray, ultrasonography or magnetic resonance imaging of the liver) were performed according 
to a standard protocol.
Results: Nineteen patients (12.5%) were diagnosed with metastasis during follow-up time 
after treatment for choroidal melanoma. Thirteen patients (10.7%) of the irradiation group and 
6 patients (19.3%) of the enucleation group were diagnosed with metastasis. Eight patients (6.6%) 
of the irradiation group and 5 patients (16.1%) of the enucleation group were diagnosed with 
liver metastasis. Ocular complications after proton beam irradiation were recorded. Fifty-nine 
patients (48.7%) of the irradiation group presented with cataract. Other complications were 
retinal detachment, retinopathy, vitreous haemorrhage, iris neovascularization, neovascular 
glaucoma, optic neuropathy, and corneal opaciﬁ  cation.
Conclusions: In our series, 10.7% of the irradiation group and 19.3% of the enucleation group 
were diagnosed with metastasis. The liver was the most common site of metastasis in both 
groups. Cataract was the most common complication in the irradiation group.
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Introduction
Choroidal melanoma arises from melanocytes within the choroid. It is the most 
common primary intraocular cancer in adults. Because this cancer is often asymp-
tomatic, it is often diagnosed after a routine eye examination, unless the patient’s 
central vision is affected. Until about 1970, enucleation was the standard treatment. 
In the early 1970s, radiotherapy and other treatment approaches, with the goal of 
preserving the eye, became increasingly popular. External beam irradiation using 
charged particles, such as protons may conserve a useful level of vision, depending 
on the size of the tumor and its location with respect to the optic disc and macula. 
Protons deposit most of their energy near the end of their range, resulting in a uni-
form and highly localized dose being deposited largely in the tumor, sparing adjacent 
healthy tissue. Furthermore, as diagnostic aids and skills improved, misdiagnosis 
rates declined. Choroidal melanoma has a well-documented capacity to metastasize 
hematogenously. The liver is the most common site of metastatic disease (Einhorn 
et al 1974; Char 1978; Zakka et al 1980; Rajpal et al 1983; Diener-West et al 2001; Clinical Ophthalmology 2008:2(4) 990
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Kath et al 1993; Bedikian et al 1995; COMS 2001, 2004, 
2005). Diagnosis of metastasis is often followed by rapid 
physical decline of the patient and treatment is generally 
ineffective (Albert et al 1992). The median time from diag-
nosis of liver metastasis to death is approximately 6 months. 
After diagnosis of choroidal melanoma, patients are screened 
for metastasis 6-monthly or annually, using liver function 
tests (LFTs) and imaging studies. More recently routine 
screening by ultrasonography of the liver and a panel of 
LFTs have been recommended (Donoso et al 1985; Donoso 
et al 1985; Pach and Robertson 1986; COMS 1995; Hicks 
1998; Eskelin et al 1999). Our primary aim was to study 
the time interval between a diagnosis of melanoma and a 
diagnosis of metastasis, and the rates and sites of metastasis 
during follow-up time in our patients. A secondary aim was 
to record ocular complications after proton beam irradiation 
(Seddon et al 1986).
Methods
One hundred and ﬁ  fty-two eyes of 152 patients with primary 
choroidal melanoma, whose primary treatment was either 
proton beam irradiation or enucleation, were included in 
the study. The irradiation group included 121 patients. The 
enucleation group included 31 patients. Of these 152 patients, 
69 were male and 83 female. The patients were treated 
between 1992 and 2006. Subjects with clinical evidence 
of metastatic disease at the time of treatment or prior to 
the treatment of their intraocular tumor were excluded. All 
patients gave written consent before treatment.
Initial evaluation included
Ophthalmic examination
Slit-lamp examination, biomicroscopy, indirect ophthalmos-
copy, fundus photographs and A-scan and B-scan ultraso-
nography. Tumor height was measured and used to classify 
a tumor as small (1 mm to 2.5 mm in apical height), medium 
(2.5 mm to 10 mm) or large (10 mm in apical height). 
Tumor location and associated features, such as secondary 
retinal detachment and hemorrhage were recorded. The initial 
evaluation also included ﬂ  uorescein and indocyanine green 
angiography, computed tomography (CT), and/or magnetic 
resonance imaging (MRI).
Systemic evaluation
Complete blood count, liver function tests (aspartate ami-
notranspherase [AST], alanine aminotranspherase [ALT], 
alkaline phosphatase [APH], gamma-glutamyl transpeptidase 
[γ-GT], lactate dehydrogenase [LDH], carcinoembryonic 
antigen [CEA]). Ultrasound and CT or MRI evaluation 
of the abdominal organs (especially the liver) and chest 
radiograph.
Proton beam irradiation was performed at Paul Scherrer 
Institute ( Villigen, Switzerland). The patients from the proton 
beam irradiation group were admitted approximately two 
weeks before the scheduled date of irradiation. In the surgical 
suite, the tumor was localized using transillumination and 
indirect ophthalmoscopy, and four tantalum rings measuring 
2.5 millimeters in diameter were sutured to the sclera to serve 
as references marking the tumor edges. Tumors located too 
far anteriorly were diagrammed using precise measurements, 
without the tantalum rings.
During the irradiation sessions, the patient was seated and 
the head was immobilized using a custom-molded plastic 
mask. Lid retractors were used to remove the lid from the 
radiation ﬁ  eld, and the patient was asked to ﬁ  x his or her 
gaze on a light attached to the proton collimator. The eye 
was viewed on a closed circuit television camera using high 
magniﬁ  cation, to detect any deviation from the indicated 
direction of gaze. An imaging system was used to verify the 
eye’s precise position during the treatment.
A computer planning program was used to target the 
proton beam. Provided with the necessary data, the computer 
generated a three-dimensional model of the eye and tumor, 
which could be viewed from any desired angle. At the time 
the model also calculated the best direction of gaze, ideal 
shape of the ﬁ  eld deﬁ  ning apertures, proton range and range 
modulations, the structures lying in the path of the beam, and 
what the viewer should see in the alignment ﬁ  lm used when 
aiming the beam. The radiation dose was 60 cobalt Gray 
equivalents delivered in 4 equal fractions.
Enucleation was performed at the Department of Ophthal-
mology of the University of Athens. The surgical technique 
consisted of peritomy for 360° at the limbus. The rectus 
muscles were individually hooked and cut with scissors 
near their insertion into the sclera. The superior and inferior 
oblique muscles were hooked with two muscle hooks and 
cut. The enucleation scissors were placed between Tenon’s 
capsule and the sclera, the optic nerve was cut and the eye 
removed. An orbital implant (hydroxyapatite sphere) was 
placed in the socket and the muscles were sutured to the 
implant.
Following enucleation, eyes were processed for histo-
pathologic conﬁ  rmation of the diagnosis at the Pathology 
Laboratory of Athens General Hospital. The patients were 
re-examined 6-monthly for the ﬁ  rst 5 years and annually 
thereafter. Follow-up evaluation included:Clinical Ophthalmology 2008:2(4) 991
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Ophthalmic examination
Slit-lamp examination, biomicroscopy, indirect ophthalmos-
copy, fundus photographs and A-scan and B-scan ultraso-
nography. Tumor height was measured.
Systemic evaluation
Complete blood count, liver function tests (AST, ALT, 
APH, γ-GT, LDH, CEA). Ultrasound evaluation of the 
abdominal organs (especially the liver). In case of abnormal 
ﬁ  ndings, CT or MRI scan of the liver and/or biopsy or cyto-
logic tests were required to conﬁ  rm or rule out metastatic 
disease.
Ocular (anterior and posterior segment) complications of 
proton beam irradiation were recorded.
Results
Tumor thickness according to B-scan ultrasonography, 
tumor location according to binocular indirect ophthal-
moscopy, and Goldmann triple mirror examination were 
recorded. In the enucleation group the affected eye was 
the right one in 18 (58%) patients and the left one in 13 
(42%). Tumor thickness ranged from 4.6 mm to 13.4 mm 
with a mean value of 9.7 mm. Tumor location was supe-
rior in 6 (19.4%) patients, inferior in 4 (12.9%) patients, 
temporal in 7 (22.6%) patients, nasal in 4 (12.9%) patients, 
superior/temporal in 2 (6.4%) patients, inferior/temporal 
in 4 (12.9%) patients, and inferior/nasal in 4 (12.9%) 
patients (Figure 1).
In the irradiation group, the affected eye was the right 
one in 57 (47%) patients and the left one in 64 (53%). 
Tumor thickness ranged from 2.6 mm to 13.4 mm with 
a mean value of 7.3 mm. Tumor location was superior in 
22 (18.2%) patients, inferior in 18 (14.9%) patients, tem-
poral in 20 (16.5%) patients, nasal in 8 (6.6%) patients, 
superior/temporal in 13 (10.7%) patients, superior/nasal in 
4 (3.3%) patients, inferior/temporal in 26 (21.5%) patients 
and inferior/nasal in 10 (8.3%) patients (Figure 1).
Of the152 patients in our study, 31 were treated by 
enucleation between 1992 and 2006 (16 males, 15 females). 
The average age of patients was 60.8 years. The median 
follow-up period was 60 months (5 years). Of the 31 patients, 
6 (19.3%) were diagnosed with metastasis (5 males, 1 female). 
The metastatic sites included: liver (5 patients, 16.1% of 
enucleation group, 83.3% of the patients with metastasis) 
and skin (1 patient, 3.2% of enucleation group, 16.7% of the 
patients with metastasis) (Figure 2).
The median interval time from diagnosis of choroidal 
melanoma to diagnosis of metastasis was 29.5 months 
(2.46 years). At 5 years, 5 patients were diagnosed with 
metastasis (16.1% of enucleation group, 83.3% of patients 
with metastasis).
Between 1992 and 2006, 121 patients were treated by 
proton beam irradiation (53 males, 68 females). The average 
age of patients was 64.2 years. The median follow-up period 
was 79.6 months (6.6 years). Thirteen patients (10.7%) 
were diagnosed with metastasis (7 males, 6 females). 
The metastatic sites included: liver (8 patients, 6.6% of 
irradiation group, 61.5% of the patients with metastasis), 
lung (2 patients, 1.6% of irradiation group, 15.4% of the 
patients with metastasis), brain (1 patient, 0.8% of irradia-
tion group, 7.7% of the patients with metastasis), thyroid 
(1 patient, 0.8% of irradiation group, 7.7% of the patients 
with metastasis), and colon (1 patient, 0.8% of irradiation 
group, 7.7% of the patients with metastasis) (Figure 2). 
The median interval of time from diagnosis of choroidal 
melanoma to the diagnosis of metastasis was 44.8 months 
(3.7 years). At 5 years, 10 patients were diagnosed with 
metastasis (8.3% of irradiation group, 76.9% of patients 
with metastasis).
Ocular complications were recorded after proton beam 
irradiation, according to slit-lamp examination, biomicros-
copy, indirect ophthalmoscopy, fundus photographs, and 
A-scan and B-scan ultrasonography. Anterior segment com-
plications were recorded in 99 (81.8%) patients and posterior 
segment complications in 71 (58.7%) patients. Cataract was 
recorded in 59 (48.7%) patients, iris neovascularization in 
17 (14%) patients, neovascular glaucoma in 14 (11.6%) 
patients, and corneal opaciﬁ  cation in 9 (7.4%) patients. 
Secondary retinal detachment was recorded in 25 (20.7%) 
patients, retinopathy in 17 (14%) patients, vitreous 
hemorrhage in 17 (14%) patients and optic neuropathy in 
12 (9.9%) patients (Figure 3).
Discussion
For more than a century, enucleation has been the standard 
treatment for choroidal melanoma. However, concerns about 
enucleation, especially possible tumor spread caused by manip-
ulation of the eye during surgery, plus vision loss and the poor 
cosmetic outcome, have made irradiation therapy a popular 
alternative. When patients are deciding on their treatment for 
choroidal melanoma, the major inﬂ  uences on their decision are 
fear of death due to cancer, and concerns about the prognosis of 
vision in the affected eye. Many ophthalmologists assume that 
better results can be achieved with irradiation therapy, because 
this form of treatment potentially allows the retention of some 
vision and avoids the perception of disﬁ  gurement.Clinical Ophthalmology 2008:2(4) 992
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Figure 3 The chart clearly demonstrates the complications of proton beam irradiation.
Abbreviations: CAT, cataract; IN, iris neovascularization; NG, neovascular glaucoma; CO, corneal opaciﬁ  cation; RD, retinal detachment; RET, retinopathy; VH, vitreous 
hemorrhage; ON, optic neuropathy.
Figure 2 Metastatic sites of the two treatment groups. In the enucleation group the metastatic sites appear in light blue, and in the irradiation group appear in dark blue.
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Figure 1 Chart demonstrating tumor location of the enucleation group (light blue) and the irradiation group (dark blue).
Abbreviations: S, superior quadrant; I, inferior quadrant; T, temporal quadrant; N, nasal quadrant; S/T, superior/temporal quadrant; I/T, inferior/temporal quadrant; I/N, 
inferior/nasal quadrant.Clinical Ophthalmology 2008:2(4) 993
Metastasis rates after treatment for choroidal melanoma
A 1986 study (Gragoudas et al 1987) showed a 20% 
cumulative risk of developing metastasis 5 years after 
irradiation, based on 128 patients followed for a median 
of 5.4 years. In a study (Gragoudas et al 1988) of 780 eyes 
(which included many of the 128 noted above) followed for 
a median of 2.2 years, 8% of that study population actually 
developed metastases, the median time to detection being 
2.1 years. Based on Kaplan-Meier probability curves, the 
same 5-year estimate of a 20% cumulative risk of metastasis 
was determined. Eighty percent to 90% of metastases from 
uveal melanoma occurred in the liver in those patients, less 
common sites being the skin and lung.
In our study we recorded the tumor location, the rates 
and sites of metastasis, and the time from diagnosis of 
melanoma to diagnosis of metastasis. In the enucleation 
group, the most common location was temporal (22.6%; 
7 patients). Six patients (19.3%) were diagnosed with 
metastasis. Liver was the most common site (83.3%). 
The median time from diagnosis of choroidal melanoma 
to diagnosis of metastasis was 29.5 months (2.46 years). 
Five of the 6 patients with metastasis (83.3%) were diag-
nosed within the ﬁ  rst 5 years after treatment (enucleation). 
In the irradiation group, the most common location was 
inferior/temporal (21.5%; 26 patients). Thirteen patients 
(10.7%) were diagnosed with metastasis. The liver was 
the most common site (61.5%). The median time from 
diagnosis of choroidal melanoma to diagnosis of metastasis 
was 44.8 months (3.7 years). Ten of the 13 patients with 
metastasis (76.9%) were diagnosed within the ﬁ  rst 5 years 
after treatment (irradiation).
Important prognostic factors for death from metastatic 
melanoma include the size of the tumor (the larger the 
tumor, the worse the prognosis), the location of the tumor 
(tumors within the ciliary body are associated with a poorer 
prognosis than those conﬁ  ned to the choroid), the age of the 
patient at the time of diagnosis (the older the patient, the 
worse the short-term survival prognosis) and extrascleral 
tumor extension (Augsburger and Gamel 1990). Patients 
with choroidal melanoma are advised to undergo periodic 
examination, blood tests for liver enzyme levels and imaging 
studies, such as chest radiographs and ultrasonography or 
MRI of the liver. We agree with other studies (Hicks 1998; 
Eskelin et al 1999) that periodic screening for metastatic 
uveal melanoma is primarily beneﬁ  cial, when effective treat-
ment is available or when patients are eligible as candidates 
for clinical trials of promising treatment. Such therapies are 
needed given the potentially frequent occurrence of micro-
metastasis at the time of diagnosis of choroidal melanoma 
and the high incidence of metastasis detected clinically after 
diagnosis of the primary tumor.
Many treated eyes eventually lose a substantial amount 
of vision, as a consequence of complications after radiation 
therapy. Factors that inﬂ  uence how much vision will be lost 
include the location of the posterior edge of the tumor relative 
to the optic disc and fovea, the visual acuity before treat-
ment, the presence or absence of macular retinal detachment, 
and the thickness of the tumor. Some systemic factors, such 
as diabetes mellitus, may also worsen a patient’s prognosis for 
retention of useful vision (Seddon et al 1986). Retinal detach-
ment, optic neuropathy, radiation retinopathy, neovascular 
glaucoma (Kim et al 1986; Summanen et al 1996; Daftari et al 
1997), vitreous hemorrhage, and cataract (Meecham et al 1994; 
Gragoudas et al 1995) have emerged consistently as causes of 
visual loss in proton beam-irradiated eyes. Establishing which 
of these conditions is most inﬂ  uential in any given case may 
cause difﬁ  culty, as they may occur in the same patient, in whom 
the presence of a cataract may further hamper a view of the 
fundus. In our study, irradiation-related complications involv-
ing the anterior segment, which contributed to a decline in 
visual acuity or eye loss, included cataract (59 patients; 48.7%), 
neovascular glaucoma (14 patients; 11.6%), and corneal neo-
vascularization and opaciﬁ  cation (9 patients; 7.4%).
Gragoudas and colleagues (1995) showed that 42% of 
383 patients who received proton beam irradiation for uveal 
melanoma, developed new posterior subcapsular opacities in 
direct proportion to the dose of radiation received by the lens 
in the irradiated eye. This result was determined by a com-
puter-generated dose-volume assessment routinely calculated 
at the time of irradiation. Cortical and sclerotic opacities were 
found to be correlated only with age in this study. Cataract 
extraction is feasible in these patients and can restore vision in 
some (Augsburger and Shields 1985; Fish et al 1991; Gragou-
das et al 1992). Panretinal photocoagulation can substantially 
reduce the severity of neovascular glaucoma and reduce the 
risk of enucleation by half (Kim et al 1986).
In our study, posterior segment complications included 
secondary retinal detachment (25 patients; 20.7%), radiation 
retinopathy (17 patients; 14%), vitreous hemorrhage 
(17 patients; 14%), and radiation neuropathy (12 patients; 
9.9%). Maculopathy affects central vision (Gragoudas 
et al 1992; Gunduz et al 1999; Guyer et al 1992), whereas 
papillopathy can lead to total loss of vision (Guyer et al 
1992; Gragoudas et al 1999). Some eyes eventually become 
severely painful, usually because of neovascular glaucoma. 
Patients who develop a blind, painful eye must undergo 
enucleation (Kellner et al 1993).Clinical Ophthalmology 2008:2(4) 994
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Preservation of the eye and useful vision in many 
patients are the obvious advantages of conservative treat-
ment with radiation compared with enucleation. However 
questions have been raised regarding the efﬁ  cacy of this 
treatment in limiting metastatic spread of the tumor. 
Observational studies (Egan et al 1989; Seddon et al 1990; 
Augsburger et al 1986) comparing irradiation with enucle-
ation have indicated no signiﬁ  cant differences in survival 
rates. In the Collaborative Ocular Melanoma Study (Adams 
et al 1998), overall 5-year mortality rates were comparable 
in patients treated by enucleation and by plaque radio-
therapy (iodine 125). Proton irradiation is highly successful 
in achieving local control of intraocular melanoma. Many 
patients maintain some degree of function in the eye for long 
periods after treatment. Overall rates of metastatic disease 
are comparable to those observed after enucleation; thus, 
enucleation should be limited to patients with large tumors 
in whom the eye is unlikely to be salvaged by irradiation. 
Doubtless continued reﬁ  nement of current methods, and 
development of new techniques, will further improve the 
outlook of patients with uveal melanomas.
Conclusion
In our series, 10.7% of the irradiation group and 19.3% of 
the enucleation group were diagnosed with metastasis. This 
difference is attributed to the larger tumor dimensions in 
patients of the enucleation group, given the observed correla-
tion between increased metastasis rate and increased size of 
choroidal melanoma. The liver was the most common site of 
metastasis in both groups. Prognosis after metastatic disease 
remains poor. Effective methods are needed to prevent, diag-
nose, and treat metastasis from choroidal melanoma.
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